Holen Sie sich die Stockscreener-App
1.49
3.87%
-0.06
Handel nachbörslich:
1.50
0.01
+0.67%
Schlusskurs vom Vortag:
$1.55
Offen:
$1.55
24-Stunden-Volumen:
346.62K
Relative Volume:
0.75
Marktkapitalisierung:
$39.61M
Einnahmen:
$50,000
Nettoeinkommen (Verlust:
$-45.93M
KGV:
-0.7744
EPS:
-1.9241
Netto-Cashflow:
$-23.62M
1W Leistung:
+10.37%
1M Leistung:
+2.76%
6M Leistung:
-0.67%
1J Leistung:
-81.04%
1-Tages-Spanne:
$1.455
$1.565
1-Wochen-Bereich:
$1.31
$1.79
52-Wochen-Spanne:
$1.09
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Firmenname
Inmune Bio Inc
Sektor
Branche
Telefon
(858) 964-3720
Adresse
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.49 | 41.21M | 50,000 | -45.93M | -23.62M | -1.9241 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-01 | Herabstufung | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-05-24 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-21 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-22 | Bestätigt | Maxim Group | Buy |
| 2020-09-01 | Eingeleitet | BTIG Research | Buy |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com
Inmune Bio stock (US45764T1060): Year-end 2025 results and update in focus - AD HOC NEWS
INmune Bio publishes Alzheimer’s trial results in journal - Investing.com UK
INMB Shows Promising Alzheimer's Results in MINDFuL Trial - GuruFocus
INmune Bio: Interview With Co-Founder & CEO David Moss About The Immunotherapies Company - Pulse 2.0
INmune Bio publishes Alzheimer’s trial results in journal By Investing.com - Investing.com South Africa
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - The Manila Times
Alzheimer’s drug XPro shows directionally consistent benefits, no ARIA - Stock Titan
INmune Bio Receives FDA Fast Track for XPro - TipRanks
INMB Secures Fast Track Designation for Alzheimer's Treatment - GuruFocus
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
INmune Bio (INMB) Stock: Up +14.73%, Key Resistance at $1.76 2026-05-14Expert Entry Points - newser.com
INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment - Pluang
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug By Investing.com - Investing.com South Africa
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug - Investing.com
INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease - marketscreener.com
INmune Bio receives FDA fast track status for Alzheimer’s drug - Investing.com
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - The Manila Times
INmune Bio receives FDA fast track status for Alzheimer’s drug By Investing.com - Investing.com UK
FDA Fast Tracks brain-inflammation drug for early Alzheimer’s - Stock Titan
INmune Bio (INMB) Q1 2026 Earnings Transcript - AOL.com
TradingKey - TradingKey
INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey
INMB: INmune BioInteractive Chart - Zacks Investment Research
Expanding partnership aims to advance stem cell therapy to treat RDEB - Epidermolysis Bullosa News
Q1 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
INmune Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
INMUNE BIO ($INMB) Releases Q1 2026 Earnings - Moomoo
Transcript : INmune Bio Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips - Investing.com
INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum - ChartMill
INmune Bio (NASDAQ: INMB) posts Q1 loss and flags going concern risks - Stock Titan
Alzheimer's drug moves toward Phase 2b/3 as CORDStrom nears UK filing - Stock Titan
Press Release: INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - Moomoo
INmune Bio Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
INmune Bio expands collaboration with Anthony Nolan charity By Investing.com - Investing.com Australia
INmune Bio expands collaboration with Anthony Nolan charity - Investing.com UK
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - 富途牛牛
INmune Bio Expands Cord Tissue License for CORDStrom Platform - TipRanks
Inmune Bio And Anthony Nolan Announce Strategic Expansion - TradingView
INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases - The Manila Times
Stem cell supply deal broadens CORDStrom push into rare skin disease, cancer - Stock Titan
A new biotech coalition says the U.S. needs a national innovation plan - Stock Titan
Finanzdaten der Inmune Bio Inc-Aktie (INMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):